After a failed Phase 3 trial in August 2020 with its CaPre lead drug candidate for patients with severe hypertriglyceridemia, Acasti Pharma (NASDAQ, TSXV:ACST) has transitioned into the rare and orphan disease sector...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
111, Inc. selected to 2021 China Top 20 Internet Healthcare Companies list
111, Inc. (NASDAQ:YI) was selected as one of the 2021 Top 20 Internet Healthcare Enterprises in China for its innovation and promotion in the internet+healthcare field and its transformative platform serving the...
VistaGen expands PH948 in Phase 2a trial for adjustment disorder
VistaGen Therapeutics (NASDAQ:VTGN) initiated a Phase 2a clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with adjustment disorder with anxiety...
FDA accepts Altamira 510(k) application for Bentrio
Altamira Therapeutics’ (NASDAQ:CYTO) 510(k) application for premarket clearance for its Bentrio nasal spray for protection against airborne allergens was accepted for review by the FDA. The application now moves to a...
Maxim starts Kazia Therapeutics at buy; PT $18
Maxim Group initiated coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and $18 price target. The stock closed at $10.71 on Oct. 13. Kazia is developing two oncology drug candidates: paxalisib, for brain...
Labster to acquire UbiSim in virtual reality training expansion
Labster, a leading platform for virtual labs and interactive science based in Denmark, signed a definitive agreement to acquire UbiSim, a virtual reality training platform for nursing, in a move to further transform...
HCW starts Progenity at buy; PT $4
H.C. Wainwright launched coverage of Progenity (NASDAQ:PROG) with a “buy” rating and price target of $4. The stock closed at $2.04 on Oct. 13. Progenity’s differentiated R&D pipeline primarily focuses on employing...
Ladenburg starts Renovacor at buy; PT $22
Ladenburg Thalmann initiated coverage of Renovacor (NASDAQ:RCOR) with a “buy” rating and $22 price target. The stock closed at $7.93 on Oct. 13. Renovacor is a preclinical-stage biotech company focused on developing...
Ladenburg cuts Ardelyx to neutral from buy
Ladenburg Thalmann downgraded Ardelyx (NASDAQ:ARDX) to “neutral” from “buy” and removed its price target, citing an unproductive post-complete response letter (CRL) Type A meeting with the FDA. The stock closed at $1.09...
BTIG cuts Neuronetics to neutral
BTIG downgraded Neuronetics (NASDAQ:STIM) to “neutral” and removed its price target, citing disappointing third quarter preliminary revenue and “perplexing fourth quarter guidance.” The stock closed at $6.40 on Oct. 12...
IntelGenx to resume Phase 2a patient screening with Montelukast VersaFilm in AD
IntelGenx (TSX:IGX; OTCQB:IGXT) intends to resume patient screening in the ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) following Health Canada’s...
Titan Pharma, MUSC Foundation in research, option license agreement
Titan Pharmaceuticals (NASDAQ:TTNP) entered into a research and option license agreement with the MUSC Foundation for Research Development (MUSC FRD) and will conduct certain research, evaluation, proof-of-concept...
Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs
Supernus Pharmaceuticals (NASDAQ:SUPN) agreed to acquire Adamas Pharmaceuticals (NASDAQ:ADMS) in a tender offer for $8.10 a share in cash, or about $400-million plus two non-tradable contingent value rights (CVR). The...
Just a few of the companies we’ve highlighted along the way
